查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1476380

到 2030 年急性癫痫群聚市场预测：按产品类型、给药途径、分销管道、最终用户和地区进行的全球分析

Acute Repetitive Seizures Market Forecasts to 2030 - Global Analysis By Product (Diastat Rectal Gel, AZ-002, NRL-1, USL-261 and Other Products), Drug Type, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球急性丛集性癫痫市场规模为 29 亿美元，预计到 2030 年将达到 76 亿美元，预测期内复合年增长率为 14.4%。

急性重复性癫痫发作 (ARS) 是在相对较短的时间内（通常在 24 小时内）连续发生的癫痫发作。这些发作的特征是反覆发作，儘管采取了正常的癫痫发作控制措施（例如遵守用药），也可能发生。这些癫痫发作可能发生在多种类型的癫痫中，如果不能迅速控制，可能会危及生命，因此需要紧急医疗护理来控制癫痫发作并防止进一步癫痫发作。

据世界卫生组织 (WHO) 称，癫痫是一种神经系统疾病，影响全球约 5,000 万人。

癫痫盛行率上升

市场对癫痫盛行率不断上升感到担忧。这一趋势表明越来越多的人口受到反覆出现和不可预测的攻击的影响，因此需要先进的治疗性介入和管理策略。癫痫患者数量的迅速增加凸显了对创新治疗、个人化护理计划和加强宣传宣传活动的迫切需要，以应对这种神经系统疾病患者面临的复杂挑战。

缺乏意识

儘管癫痫治疗取得了重大进展，但市场认知度仍然很低。许多人，包括医疗保健提供者和公众，可能不完全了解患者面临的挑战或可用的治疗方案。这种意识差距阻碍了及时诊断、适当的管理和获得创新治疗方法，并需要有针对性的教育和宣传工作来改善管理结果。

新药开发

目前正在研究新的作用机制，例如针对参与癫痫发作的特定离子通道和神经传导物质系统。此外，鼻腔和经皮製剂等药物传递方法的进步旨在提高患者的依从性和治疗结果。这些努力意味着采取积极主动的方法来优化癫痫患者的治疗方案。

治疗费用高

急性復发性癫痫（ARS）市场的高治疗成本是一个重大问题，并且常常超出患者和医疗保健系统的财务能力。治疗费用包括诊断测试、药物、住院和持续监测，这是一笔巨大的经济负担。这种成本障碍可能会限制获得基本治疗方法的机会，并影响患者的治疗结果和生活品质。

COVID-19 的影响：

COVID-19 大流行对急性復发性癫痫发作 (ARS) 市场产生了重大影响。获得医疗服务的机会受到干扰，导致许多患者的诊断和治疗延误。临床试验和研究计画也面临挫折，影响了新治疗方法的发展。然而，远端医疗和远端监控的普及提供了患者管理的替代方法。

巴比妥类药物预计在预测期内成为最大的药物市场

巴比妥类药物预计在预测期内将是最大的。巴比妥酸盐药长期以来一直是一种选择，但由于安全问题和更有效的新药物的开发，其使用已经减少。在市场上，巴比妥酸盐药在其他治疗方法无效或禁忌的特定情况下发挥特殊作用。儘管用途有限，但Phenobarbital类巴比妥酸盐药对于某些患者可能是可行的，特别是在资源有限的情况下或根据个别患者的需求进行定制时，它仍然是一种选择。

预计居家照护产业在预测期内复合年增长率最高。

预计居家照护环境领域在预测期内将经历最高的复合年增长率。家庭护理环境包括各种服务，例如监控设备、看护者培训和紧急应变计划。随着远端医疗和远端监控技术的进步，居家照护环境变得越来越复杂，提高了个人管理急性发作群的便利性和舒适性，同时实现了即时干预并改善了患者的治疗效果。

占比最大的地区：

由于意识提高、诊断技术改进和患者数量增加等因素，预计北美在预测期内将占据最大的市场占有率。该市场的主要参与者专注于开发先进的治疗方法和药物，以满足未满足的医疗需求。此外，政府措施和医疗改革在提高辅助生殖服务治疗的可及性方面发挥着关键作用，为该地区的市场扩张带来了光明的前景。

复合年增长率最高的地区：

预计亚太地区在预测期内复合年增长率最高。 ARS 是一种影响该地区大量人口的严重疾病。认识宣传活动和改进的诊断方法正在增加我们对这种疾病的了解，并增加对有效治疗方法的需求。製药公司、研究机构和医疗保健提供者之间的竞争正在推动 ARS 治疗的创新和降低价格。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球急性丛集性癫痫市场：依产品

  • Diastat直肠凝胶
  • AZ-002
  • NRL-1
  • USL-261
  • 其他产品

第六章全球急性丛集性癫痫市场：依药物类型

  • 苯二氮平类
  • 巴比妥酸
  • 抗癫痫药 (AED)
  • 其他药物种类

第七章全球急性丛集性癫痫市场：依途径

  • 鼻腔
  • 口服
  • 静脉

第八章全球急性丛集性癫痫市场：依通路分类

  • 专科诊所
  • 零售药房
  • 医院
  • 网路药房

第九章全球急性丛集性癫痫市场：依最终使用者分类

  • 居家照护环境
  • 诊所
  • 其他最终用户

第10章全球急性丛集性癫痫市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Bausch Health Companies Inc.
  • UCB Pharma
  • Eisai Co., Ltd.
  • SK Biopharmaceuticals Co., Ltd.
  • Valeant Pharmaceuticals North America LLC
  • Sunovion Pharmaceuticals
  • GW Pharmaceuticals
  • Pfizer Inc.
  • Marinus Pharmaceuticals
  • Neurelis, Inc.
  • Sanofi
  • Novartis AG
  • Alexza
  • Veriton Pharma
Product Code: SMRC25926

According to Stratistics MRC, the Global Acute Repetitive Seizures Market is accounted for $2.9 billion in 2023 and is expected to reach $7.6 billion by 2030 growing at a CAGR of 14.4% during the forecast period. Acute Repetitive Seizures (ARS) is a series of epileptic seizures that occur in rapid succession within a relatively short period, typically within 24 hours. These seizures are characterized by their repetitive nature and can occur despite the person's normal seizure control measures, such as medication adherence. They can occur in various types of epilepsy and may require urgent medical attention to manage and prevent further seizures, as they can be dangerous and potentially life-threatening if not controlled promptly.

According to World Health Organization (WHO), epilepsy is a neurological condition affecting about 50 million people worldwide.

Market Dynamics:

Driver:

Rising prevalence of epilepsy

The market is witnessing a concerning rise in epilepsy prevalence. This trend indicates a growing population affected by recurrent and unpredictable seizures, necessitating advanced therapeutic interventions and management strategies. The surge in epilepsy cases within the sector underscores the pressing need for innovative treatments, personalized care plans, and heightened awareness campaigns to address the complex challenges faced by individuals grappling with this neurological disorder.

Restraint:

Lack of awareness

Despite significant advancements in epilepsy treatment, there remains a notable lack of awareness in the market. Many individuals, including healthcare providers and the general public, may not fully grasp the challenges faced by patients or the available therapeutic options. This gap in awareness hinders timely diagnosis, appropriate management, and access to innovative treatments, highlighting the need for targeted education and advocacy efforts to improve outcomes in management.

Opportunity:

Development of new drugs

Research is geared towards novel mechanisms of action, such as targeting specific ion channels or neurotransmitter systems implicated in seizure generation. Additionally, advancements in drug delivery methods, like intranasal or transdermal formulations, aim to improve patient compliance and treatment outcomes. These efforts signify a proactive approach to optimizing therapeutic options for individuals with the market.

Threat:

High cost of treatment

The high cost of treatment in the Acute Repetitive Seizures (ARS) market is a significant concern, often exceeding the financial capacities of patients and healthcare systems alike. The expenses encompass diagnostic tests, medications, hospitalizations, and ongoing monitoring, creating a considerable financial burden. This cost barrier can limit access to essential therapies, impacting patient outcomes and quality of life.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Acute Repetitive Seizures (ARS) market. Access to healthcare services was disrupted, leading to delayed diagnosis and treatment for many patients. Clinical trials and research initiatives also faced setbacks, affecting the development of new therapies. However, telemedicine and remote monitoring gained traction, offering alternative ways to manage patients.

The barbiturates segment is expected to be the largest during the forecast period

The barbiturates segment is expected to be the largest during the forecast period. Barbiturates have been a longstanding option, but their use has declined due to safety concerns and the development of newer, more effective medications. In the market, they occupy a niche role for specific cases where other treatments have failed or are contraindicated. Despite their limited use, barbiturates like phenobarbital remain a viable option for certain patients, particularly in resource-limited settings or when tailored to individual patient needs.

The home care settings segment is expected to have the highest CAGR during the forecast period

The home care settings segment is expected to have the highest CAGR during the forecast period. These settings encompass a range of services, including monitoring equipment, caregiver training, and emergency response plans. With advancements in telemedicine and remote monitoring technologies, home care settings have become increasingly sophisticated, enabling real-time interventions and improving patient outcomes while enhancing convenience and comfort for individuals managing acute repetitive seizures.

Region with largest share:

North America is projected to hold the largest market share during the forecast period driven by factors such as increasing awareness, improved diagnostic technologies, and a growing patient population. Key players in this market focus on developing advanced therapies and medications to address unmet medical needs. Additionally, government initiatives and healthcare reforms are playing a crucial role in enhancing access to ARS treatments, leading to a promising outlook for market expansion in the region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. It is a serious condition that affects a significant number of people in the region. Awareness campaigns and improved diagnosis have contributed to a better understanding of the condition, leading to increased demand for effective treatments. Competition among pharmaceutical companies, research institutions, and healthcare providers drives innovation and affordability in ARS treatments.

Key players in the market

Some of the key players in Acute Repetitive Seizures market include Bausch Health Companies Inc., UCB Pharma, Eisai Co., Ltd., SK Biopharmaceuticals Co., Ltd., Valeant Pharmaceuticals North America LLC, Sunovion Pharmaceuticals, GW Pharmaceuticals, Pfizer Inc., Marinus Pharmaceuticals, Neurelis, Inc., Sanofi, Novartis AG, Alexza and Veriton Pharma.

Key Developments:

In May 2019, UCB declared that the U.S. FDA has permitted a New Drug Application for the company's latest anti-epileptic drug (AED) NAYZILAM(R) nasal spray CIV. It is a benzodiazepine designated for the stereotypic incidents of recurrent seizure activity and acute treatment of intermittent that are different from a patient's normal seizure form in person with epilepsy 12 years and older1.

In September 2018, Neurelis, Inc., a pharmaceutical firm based in San Diego, California, submitted a New Drug Application (NDA) to the FDA for VALTOCO as a treatment for epilepsy patients with acute repeated seizures.

Products Covered:

  • Diastat Rectal Gel
  • AZ-002
  • NRL-1
  • USL-261
  • Other Products

Drug Types Covered:

  • Benzodiazepines
  • Barbiturates
  • Antiepileptic Drugs (AEDs)
  • Other Drug Types

Route of Administrations Covered:

  • Intranasal Formulations
  • Oral
  • Intravenous

Distribution Channels Covered:

  • Specialty Clinics
  • Retail Pharmacies
  • Hospitals
  • Online Pharmacies

End Users Covered:

  • Home Care Settings
  • Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Acute Repetitive Seizures Market, By Product

  • 5.1 Introduction
  • 5.2 Diastat Rectal Gel
  • 5.3 AZ-002
  • 5.4 NRL-1
  • 5.5 USL-261
  • 5.6 Other Products

6 Global Acute Repetitive Seizures Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Benzodiazepines
  • 6.3 Barbiturates
  • 6.4 Antiepileptic Drugs (AEDs)
  • 6.5 Other Drug Types

7 Global Acute Repetitive Seizures Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intranasal Formulations
  • 7.3 Oral
  • 7.4 Intravenous

8 Global Acute Repetitive Seizures Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Specialty Clinics
  • 8.3 Retail Pharmacies
  • 8.4 Hospitals
  • 8.5 Online Pharmacies

9 Global Acute Repetitive Seizures Market, By End User

  • 9.1 Introduction
  • 9.2 Home Care Settings
  • 9.3 Clinics
  • 9.4 Other End Users

10 Global Acute Repetitive Seizures Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Bausch Health Companies Inc.
  • 12.2 UCB Pharma
  • 12.3 Eisai Co., Ltd.
  • 12.4 SK Biopharmaceuticals Co., Ltd.
  • 12.5 Valeant Pharmaceuticals North America LLC
  • 12.6 Sunovion Pharmaceuticals
  • 12.7 GW Pharmaceuticals
  • 12.8 Pfizer Inc.
  • 12.9 Marinus Pharmaceuticals
  • 12.10 Neurelis, Inc.
  • 12.11 Sanofi
  • 12.12 Novartis AG
  • 12.13 Alexza
  • 12.14 Veriton Pharma

List of Tables

  • Table 1 Global Acute Repetitive Seizures Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
  • Table 4 Global Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
  • Table 5 Global Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
  • Table 6 Global Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
  • Table 7 Global Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 9 Global Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 10 Global Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
  • Table 11 Global Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
  • Table 12 Global Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 13 Global Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 14 Global Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
  • Table 15 Global Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
  • Table 16 Global Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 17 Global Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 18 Global Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 19 Global Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 20 Global Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 21 Global Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 22 Global Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 Global Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 24 Global Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 25 Global Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 26 North America Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
  • Table 27 North America Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
  • Table 28 North America Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
  • Table 29 North America Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
  • Table 30 North America Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
  • Table 31 North America Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
  • Table 32 North America Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 33 North America Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 34 North America Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 35 North America Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
  • Table 36 North America Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
  • Table 37 North America Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 38 North America Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 39 North America Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
  • Table 40 North America Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
  • Table 41 North America Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 42 North America Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 43 North America Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 44 North America Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 45 North America Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 46 North America Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 47 North America Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
  • Table 48 North America Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 49 North America Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 50 North America Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 51 Europe Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
  • Table 52 Europe Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
  • Table 53 Europe Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
  • Table 54 Europe Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
  • Table 55 Europe Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
  • Table 56 Europe Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
  • Table 57 Europe Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 58 Europe Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 59 Europe Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 60 Europe Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
  • Table 61 Europe Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
  • Table 62 Europe Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 63 Europe Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 64 Europe Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
  • Table 65 Europe Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
  • Table 66 Europe Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 67 Europe Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 68 Europe Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 69 Europe Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 70 Europe Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 71 Europe Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 72 Europe Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
  • Table 73 Europe Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 74 Europe Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 75 Europe Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 76 Asia Pacific Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
  • Table 77 Asia Pacific Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
  • Table 78 Asia Pacific Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
  • Table 79 Asia Pacific Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
  • Table 80 Asia Pacific Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
  • Table 81 Asia Pacific Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
  • Table 82 Asia Pacific Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 83 Asia Pacific Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 84 Asia Pacific Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 85 Asia Pacific Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
  • Table 86 Asia Pacific Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
  • Table 87 Asia Pacific Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 88 Asia Pacific Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 89 Asia Pacific Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
  • Table 90 Asia Pacific Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
  • Table 91 Asia Pacific Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 92 Asia Pacific Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 93 Asia Pacific Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 94 Asia Pacific Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 95 Asia Pacific Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 96 Asia Pacific Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 97 Asia Pacific Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
  • Table 98 Asia Pacific Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 99 Asia Pacific Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 100 Asia Pacific Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 101 South America Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 South America Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
  • Table 103 South America Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
  • Table 104 South America Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
  • Table 105 South America Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
  • Table 106 South America Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
  • Table 107 South America Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 108 South America Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 109 South America Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 110 South America Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
  • Table 111 South America Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
  • Table 112 South America Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 113 South America Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 114 South America Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
  • Table 115 South America Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
  • Table 116 South America Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 117 South America Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 118 South America Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 119 South America Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 120 South America Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 121 South America Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 122 South America Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
  • Table 123 South America Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 124 South America Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 125 South America Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 126 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
  • Table 127 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
  • Table 128 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
  • Table 129 Middle East & Africa Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
  • Table 130 Middle East & Africa Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
  • Table 131 Middle East & Africa Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
  • Table 132 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 133 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 134 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 135 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
  • Table 136 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
  • Table 137 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 138 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 139 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
  • Table 140 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
  • Table 141 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 142 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 143 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 144 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 145 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 146 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 147 Middle East & Africa Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
  • Table 148 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 149 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 150 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)